Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2017
Principal Executive Offices: Canton, MA
The Company entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. to facilitate an "at-the-market" offering of its common stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of a material definitive agreement regarding potential equity issuance.
- Maximum Offering Size: Up to $60,000,000 in aggregate offering price.
- Agent Commission: Up to 3.0% of gross proceeds from the sale of shares.
- Stock Par Value: $0.001 per share.
Material Changes
The material change disclosed is the execution of the Sales Agreement dated March 13, 2017. This agreement authorizes the Company to issue and sell shares through Cantor Fitzgerald on or after March 10, 2017. The Company retains the discretion to determine the timing and amounts of sales and has no obligation to sell any shares.
Guidance, Outlook, and Risks
Management Commentary: The offering is conducted on a "commercially reasonable efforts basis." The Company or the agent may suspend or terminate the offering upon notice.
Regulatory Context: Shares will be issued pursuant to a shelf registration statement on Form S-3 (File No. 333-213964), declared effective on October 18, 2016. A prospectus supplement was filed concurrently with this report.
Risks/Contingencies: The filing explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy in any state where such offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the current market price of Collegium Pharmaceutical common stock to assess potential dilution impact.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination conditions and pricing mechanisms.
- Check subsequent filings to determine if and when shares were actually sold under this agreement.
- Confirm the status of the underlying Form S-3 shelf registration (File No. 333-213964).